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Miguel-Angel Perales, Marcel R. M. van den BrinkAllogeneic hematopoietic stem cell transplanta-
tion (allo-HSCT) is associated with deficiencies in T
and B cell reconstitution that can persist for over
a year and have been linked to increased risks of infec-
tions [1-4], disease relapse [5], and the development of
secondary malignancies [6]. Posttransplantation im-
mune reconstitution is affected by several factors, in-
cluding thymic involution associated with advanced
patient age, the conditioning regimen, HLA disparity
between donor and recipient, T cell depletion of
the graft, occurrence of graft-versus-host disease
(GVHD), and the drugs used to prevent or treat
GVHD. Total body irradiation (TBI), for example,
decreases the production of IL-7 by thymic stromal
cells, suggesting that radiation may affect normal T
cell regeneration driven by IL-7 [7]. In addition, ap-
proaches used to prevent GVHD through in vivo
(with alemtuzumab or antithymocyte globulin, ATG)
or in vitro T cell depletion also have a significant im-
pact on T cell recovery [1,8-17]. Finally, GVHD hasbeen shown to affect the thymus [18-20], and also
has a significant impact on immune recovery due to
immunosuppressive drugs required to treat GVHD
[21-26].
Different approaches have been used to assess post-
transplantation immune recovery, from relatively sim-
ple and readily available parameters such as absolute
lymphocyte count (ALC) or counts of lymphocyte sub-
sets (CD41 and CD81 T cells, NK cells, B cells), to
more complex and less routine assays of T cell reper-
toire and T cell receptor–expressing circles (TRECs)
[1-4,15-18,27-30]. ALC has been shown to be
predictive of overall survival and relapse in several
studies [15,27-30], whereas CD41 T cell count has
been shown to correlate with an increased risk of fatal
opportunistic infections [1,16]. Studies of TRECs,
which can be used as markers of thymopoiesis, have
shown more rapid recovery in younger recipients and
in recipients of conventional grafts compared to T
cell–depleted grafts [17], whereas the occurrence ofYork Avenue, Box 298, New York, NY 10065 (e-mail:
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Furthermore TREC values correlated strongly with
severe opportunistic infections [17]. Most of the
studies of immune reconstitution to date have
focused on allo-HSCT using related or unrelated
donors. In contrast, there remains relatively little data
on immune reconstitution after umbilical cord blood
(UCB) transplantation, which is increasingly being
used for patients without a matched sibling or
volunteer donor [31].
In the study by Kanda et al. [32] reported in this is-
sue of Biology of Blood and Marrow Transplantation, im-
mune parameters were studied prospectively in 95
patients undergoing ablative allo-HSCT, including
29 recipients of UCB grafts. Compared with recipients
of matched related or unrelated donor grafts, patients
who received a double UCB graft exhibited a signifi-
cant delay in T cell recovery (CD4 and CD8) until 6
months posttransplantation. These patients’ T cell re-
covery was consistent with that reported in other stud-
ies of UCB transplantation without the use of ATG
[33]. Furthermore, the delayed T cell recovery was as-
sociated with high rates of CMV reactivation in UCB
recipients, as reported previously [33]. TREC levels
were comparable in recipients of grafts from different
stem cell sources by 6 months posttransplantation, and
no differences in TCR diversity were identified at 12
months. Improved T cell recovery was associated
with higher PFS and, consistent with previous reports
[34,35], there was no significant difference in PFS.
We recently investigated TCR diversity in allo-
HSCT recipients using 5’-rapid amplification of
cDNA ends PCR with deep sequencing [36] (van
Heijst et al., NatureMedicine, in press).We found sig-
nificantly greater diversity in CD41 T cells than in
CD81 T cells, underscoring the need to study these
populations separately. When comparing stem cell
sources, we found the most rapid recovery in diversity
in UCB recipients, followed by recipients of conven-
tional grafts and T cell–depleted grafts. After 6
months, UCB recipients approximated the TCR di-
versity of healthy controls, whereas recipients of T
cell–depleted grafts had 28-fold lower CD41 and 14-
fold lower CD81T cell diversity. By 12 months, these
deficiencies improved for the CD41, but not the
CD81, T cell compartment, likely explaining the re-
sults of Kanda et al. This approach also allows the
identification and monitoring of individual clono-
types, including known clonotypes specific for viral
epitopes.
As more studies examine immune reconstitution in
recipients of UCB transplants, the following themes
are emerging: (1) There is a delay in immune recovery
early after UCB transplantation compared with related
or unrelated donor HSCT; (2) this delay persists for
approximately 6months and is associated with a higher
rate of viral infection; (3) the predominance of na€ıve Tcells in UCB grafts likely contributes to this higher
rate of viral infection; and (4) by 12 months posttrans-
plantation, immune recovery after UCB transplanta-
tion is at least on par with that seen after
conventional HSCT. Moreover, this study and other
previous reports demonstrate that immune parameters
are predictive of outcomes, including survival. The
study also provides comparative data for different
stem cell sources with clinical correlations. With the
advent of new technology, such as deep sequencing
and its ability to provide information not only on
TCR diversity but also on the frequency of specific
clonotypes over time, as well as the development of
therapeutic strategies that may enhance immune re-
covery, such as IL-7 or growth hormone [37], detailed
and comprehensive prospective studies of post-HSCT
immune reconstitution are becoming increasingly
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